



<b>Name</b>	Sung-Hoon Jung	
<b>Current Position</b>	Clinical Associate professor, Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea	
<b>Country</b>	Republic of Korea	
<b>Major Field</b>	Hematology, Multiple Myeloma, Acute lymphoblastic leukemia, Immunotherapy	

### Educational Background

2013.03 - 2015.08 Ph.D., Graduate School of Chonnam National University, Gwangju, Korea  
 2004.03 - 2006.02 Master, Graduate School of Chonnam National University, Gwangju, Korea  
 1997.03 - 2003.02 Bacheolar, Graduate School of Chonnam National University, Gwangju, Korea

### Professional Experience

2017.09 – Associate professor, Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

2016.11-2017.08 Clinical Associate Professor, Department of Hematology Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

2012.06-2016.10 Clinical Assistant Professor, Department of Hematology Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

2011.05-2012.05 Fellowship, Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea

2004.03-2008.02 Residency, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea

2003.03-2004.02 Internship, Chonnam National University Hospital, Gwangju, Korea



## Other Experience and Professional Memberships

Korean Association of Internal Medicine

Korean Society of Hematology

Korean Society of Blood and Marrow Transplantation

Member of International Myeloma Society

Member of Asian Myeloma Network

## Main Scientific Publications

1. Kim M, Lee JJ, Min CK, Lee JY, Jo JC, Yoon SS, Lim SN, Do YR, Kim K, Lee JH, Yoo KH, Bae SH, Yi JH, Jung J, Eom HS, Jung SH. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). *Ann Hematol* 2023, Online ahead of print.
2. Jung SH, Kim K, Yoon SE, Moon JH, Kim D, Kim HJ, Kim MK, Kim KH, Lee HJ, Lee JH, Kim SH, Yoo KH, Lee JH, Lee JJ. Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party. *Blood Cancer L* 2022;12(11):157
3. Thangaraj JL, Jung SH, Vo MC, Chu TH, Phan MT, Lee KH, Ahn SY, Kim M, Song GY, Ahn JS, Yang DH, Kim HJ, Cho D, Lee JJ. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model. *Cancer Immunother* 2023;72(5):1233-1246
4. Jung SH, Min CK, Lee JH, Mun YC, Bang SM, Yoon DH, Lee HS, Kim K, Lee JJ. Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909). *Bone Marrow Transplant* 2022, 57(12):1797-1802
5. Chu TH, Vo MC, Lakshmi TJ, Ahn SY, Kim M, Song GY, Yang DH, Ahn JS, Kim HJ, Jung SH, Lee JJ. Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma. *Transl Oncol* 2022;20:101413
6. Jung SH, Kwon SY, Min JJ, Bom HS, Ahn SY, Jung SY, Lee SS, Park MR, Yang DH, Ahn JS, Kim HJ, Lee JJ. <sup>18</sup>F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. *Eur J Nucl Med Mol Imaging*. 2019 Jan;46(1):107-115. doi: 10.1007/s00259-018-4114-0.
7. Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS; Korean Multiple Myeloma Working Party. Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning

---

Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). *Biol Blood Marrow Transplant.* 2018 May;24(5):923-929. doi: 10.1016/j.bbmt.2018.01.004

---